Saturday 17 October 2026
Export HKPD’s income statement to Excel — free account
Cellyan Biotechnology Co., Ltd
HKPD Healthcare Medical Distribution
Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.
0.11
0.00
0.00%
Follow HKPD
| Dec '22 | Mar '23 | Dec '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 4 | 3 |
Altman Z-Score |
— | — | — | — | 4.66 | 3.39 |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
2.85 | 2.85 | — | 6.34 | 5.84 | 7.32 |
Beneish M-Score |
— | — | — | (0.49) | (2.40) | (0.76) |
P/Operating CF |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | — | 0.00 | (0.42) | 2.21 |
EV/FCF |
0.00 | 0.00 | — | 0.00 | (0.47) | 5.00 |
Quick Ratio |
1.00 | 1.00 | 0.00 | 1.77 | 2.80 | 3.75 |
Current Ratio |
1.08 | 1.08 | 0.00 | 2.46 | 2.99 | 3.86 |
Net Debt/EBITDA |
(0.40) | (0.19) | 0.00 | 0.49 | (5.45) | (0.79) |
Debt/Assets |
3.07% | 9.13% | 0.00% | 16.76% | 19.98% | 7.34% |
Debt/Equity |
0.18 | 0.53 | — | 0.34 | 0.38 | 0.10 |
Asset Turnover |
0.00 | 3.69 | 0.00 | 2.45 | 2.25 | 1.21 |
Operating CF/Net income |
0.00 | 1.73 | 0.00 | (0.30) | (21.00) | 0.66 |
Capex/Depreciation |
— | (1.59) | — | (0.85) | (2.04) | (0.49) |
Interest Coverage |
44.99 | 44.99 | — | 19.42 | 1.34 | (7.48) |
| 0.00% | 253.80% | 0.00% | 54.96% | (0.59%) | (15.59%) | |
| 0.00% | 29.30% | 31.71% | 19.49% | (0.30%) | (10.21%) | |
ROIC |
395.14% | 175.61% | 0.00% | 19.79% | 2.11% | (6.07%) |
Return on Tangible Assets |
285.77% | 285.77% | 26.69% | 28.12% | (0.46%) | (12.35%) |
Average Days of Receivables |
59.10 | 59.10 | 0.00 | 108.94 | 92.74 | 319.30 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
13.50% | 14.00% | 0.00% | 11.32% | 10.91% | 17.83% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.00 | 1.83 | — | 2.27 | 1.99 | 0.82 |
Operating CF per Share |
— | 0.25 | — | (0.05) | 0.06 | (0.05) |
Capex per Share |
— | (0.02) | — | (0.01) | (0.02) | 0.00 |
Free Cash Flow per Share |
— | 0.24 | — | (0.06) | 0.04 | (0.05) |
Cash per Share |
0.00 | 0.08 | — | 0.09 | 0.29 | 0.01 |
Shareholders Equity per Share |
0.00 | 0.09 | — | 0.58 | 0.49 | 0.59 |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.09 | — | 0.58 | 0.49 | 0.59 |
Free Cash Flow |
— | 1.61 | — | (0.45) | 0.41 | (0.79) |
Working Capital |
0.20 | 0.20 | 4.98 | 4.63 | 5.81 | 9.14 |
Capital Expenditures |
— | (0.12) | — | (0.05) | (0.15) | (0.04) |
Net Current Asset Value |
(0.07) | (0.07) | 4.98 | 3.39 | 4.30 | 9.07 |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.01 | — | 0.00 | 0.01 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
0.00 | 0.49 | — | 0.62 | 0.68 | 1.47 |
Cash ROIC |
0.00% | 113.28% | — | (7.09%) | 4.19% | (7.39%) |
Accounts Receivable Turnover |
0.00 | 6.18 | 0.00 | 3.35 | 4.01 | 1.59 |
Accounts Payable Turnover |
0.00 | 0.00 | — | 8.86 | 11.06 | 8.94 |
Inventory Turnover |
0.00 | 51.43 | — | 23.36 | 23.97 | 26.19 |
Average Days of Payables |
0.00 | 57.60 | — | 39.37 | 37.15 | 26.48 |
Days of Inventory on Hand |
7.10 | 7.10 | — | 25.95 | 11.42 | 10.91 |
Average Receivables |
— | 2.03 | 3.51 | 4.98 | 5.07 | 8.46 |
Average Payables |
— | — | — | 1.48 | 1.62 | 1.35 |
Average Inventory |
— | 0.19 | — | 0.56 | 0.75 | 0.46 |
Average Assets |
— | 3.41 | 4.19 | 6.82 | 9.04 | 11.13 |
Average Common Equity |
— | 0.39 | — | 2.42 | 4.62 | 7.29 |
Columns are period end dates